Clinical Trials
34 trialsNCT05593094 2026-05-26
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT06324357 2026-05-26
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Phase 1/2 Recruiting
NCT06686394 2026-05-22
MK-1022-009
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04802759 2026-05-11
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07040059 2026-04-17
A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Aurigene Discovery Technologies Limited
Phase 1/2 Terminated
NCT05785741 2026-04-06
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT05081609 2026-02-24
IL Believe
Ascendis Pharma A/S
Phase 1/2 Active not recruiting
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting
NCT01084863 2025-01-24
Compare
Celltrion
Phase 1/2 Completed
NCT05555251 2024-12-16
CONTRAST
BioInvent International AB
Phase 1/2 Terminated
NCT05207722 2024-12-12
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Celularity Incorporated
Phase 1/2 Terminated
NCT03379428 2024-12-06
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
US Oncology Research
Phase 1/2 Active not recruiting
NCT04092673 2024-05-21
Zotatifin
Effector Therapeutics
Phase 1/2 Unknown
NCT00337649 2023-04-28
A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 1/2 Completed
NCT02393248 2023-01-06
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Phase 1/2 Terminated
NCT05091528 2022-08-18
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Silverback Therapeutics
Phase 1/2 Terminated
NCT02154529 2022-04-27
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Kadmon Corporation, LLC
Phase 1/2 Terminated
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT04170595 2021-03-03
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
Genor Biopharma Co., Ltd.
Phase 1/2 Unknown
NCT01271920 2020-12-08
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
Novartis
Phase 1/2 Completed
NCT00140140 2019-11-26
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Celgene
Phase 1/2 Terminated
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00398567 2018-07-24
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT00864175 2018-01-18
Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
Incyte Corporation
Phase 1/2 Terminated
NCT01512199 2017-10-18
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Daiichi Sankyo
Phase 1/2 Terminated
NCT01132664 2016-08-17
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
Novartis
Phase 1/2 Terminated
NCT01042925 2016-06-03
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
Sanofi
Phase 1/2 Completed
NCT00567879 2016-05-09
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
Novartis
Phase 1/2 Terminated
NCT01746771 2016-03-03
A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
Hanmi Pharmaceutical Company Limited
Phase 1/2 Completed
NCT02015676 2015-03-12
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer
Hoffmann-La Roche
Phase 1/2 Completed
NCT01386580 2015-01-22
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
Phase 1/2 Completed
NCT00788333 2012-07-13
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01254136 2012-01-25
Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
Incyte Corporation
Phase 1/2 Terminated
NCT00031278 2011-05-30
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Pfizer
Phase 1/2 Completed